Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29321697 | 1.00 | KRAS (0.41) | KRAS | |
| SCHEMBL29322545 | 0.95 | KRAS (0.40) | KRAS | |
| SCHEMBL32666453 | 0.92 | KRAS (0.39) | KRAS | |
| SCHEMBL30873434 | 0.88 | KRAS (0.35) | KRAS | |
| SCHEMBL29322543 | 0.88 | KRAS (0.38) | KRAS | |
| SCHEMBL29324162 | 0.87 | — | — | |
| SCHEMBL29321694 | 0.87 | KRAS (0.39) | KRAS | |
| SCHEMBL30873410 | 0.87 | KRAS (0.39) | KRAS | |
| SCHEMBL31243088 | 0.87 | KRAS (0.46) | KRAS | |
| SCHEMBL30873357 | 0.83 | KRAS (0.30) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137699-A1 | OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024083168-A1 | OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137699-A1 | OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | SCN1B, OXER1, NR3C2 | KRAS 1034/4885 |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | AZI2, HDAC5, HDAC4 | KRAS 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.